An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Donaldson Company, Inc. (NYSE: DCI) announced the acquisition of Isolere Bio, Inc., a biotechnology firm specializing in IsoTag™ reagents for biopharmaceutical purification. This strategic acquisition aims to enhance Donaldson's Life Sciences portfolio, focusing on the purification of viral vectors for cell and gene therapies. Isolere's innovative technology is expected to improve product quality and speed up delivery timelines for therapies. Donaldson plans to leverage synergies from previous acquisitions and its strong balance sheet to accelerate Isolere's growth.
Positive
Acquisition strengthens Donaldson's Life Sciences segment.
IsoTag technology enhances purification processes for biopharmaceuticals.
Potential for accelerated revenue growth from Isolere's commercialization.
Negative
None.
MINNEAPOLIS--(BUSINESS WIRE)--
Donaldson Company, Inc. (NYSE: DCI), a leading worldwide provider of innovative filtration products and solutions, today announced the acquisition of Isolere Bio, Inc. (Isolere), an early-stage biotechnology company that develops novel and proprietary IsoTag™ reagents and accompanying filtration processes used for the purification and streamlined manufacturing of biopharmaceuticals. Aimed initially at the purification of viral vectors used for cell and gene therapies, IsoTag™ reagents are designed to substantially improve product quality and purity with faster timelines compared to competing solutions, enabling accelerated and more affordable delivery of life-changing therapies to patients globally.
“With the integral addition of Isolere to our Life Sciences portfolio, Donaldson is positioned to create premier separation and filtration solutions for emerging genetic-based drugs,” said Tod Carpenter, chairman, president and chief executive officer of Donaldson. “We look forward to accelerating Isolere’s growth trajectory through sales synergies from our recent acquisitions of Solaris Biotechnology and Purilogics and through the strength of our balance sheet.”
“Isolere is thrilled to join the Donaldson family and bring our novel affinity-phase separation technology to market,” said Kelli Luginbuhl, Ph.D, co-founder and chief executive officer of Isolere. “Our technology, complemented by Donaldson’s filtration excellence, is part of a larger vision to bring end-to-end solutions to the life sciences industry.”
Founded in 2017 by Kelli Luginbuhl, Ph.D, Professor Ashutosh Chilkoti, and Joe McMahon, Isolere is headquartered in Durham, North Carolina. Once commercialized, revenue from Isolere will be reported within the Donaldson Life Sciences segment.
Statements in this release regarding future events and expectations, such as forecasts, plans, trends and projections relating to the Company’s business and financial performance, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are identified by words or phrases such as “will likely result,” “are expected to,” “will continue,” “will allow,” “estimate,” “project,” “believe,” “expect,” “anticipate,” “forecast,” “plan” and similar expressions. These forward-looking statements speak only as of the date such statements are made and are subject to risks and uncertainties that could affect the Company’s performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed. These factors include, but are not limited to, challenges in global operations; impacts of global economic, industrial and political conditions on product demand, including the Russia and Ukraine conflict; impacts from unexpected events, including the COVID-19 pandemic; effects of unavailable raw materials or material cost inflation; inability to attract and retain qualified personnel; inability to meet customer demand; inability to maintain competitive advantages; threats from disruptive technologies; effects of highly competitive markets with pricing pressure; exposure to customer concentration in certain cyclical industries; inability to manage productivity improvements; results of execution of any acquisition, divestiture and other strategic transactions; vulnerabilities associated with information technology systems and security; inability to protect and enforce intellectual property rights; costs associated with governmental laws and regulations; impacts of foreign currency fluctuations; and effects of changes in capital and credit markets. These and other factors are described in Part I, Item 1A, “Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2022. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.
About Donaldson Company, Inc.
Founded in 1915, Donaldson (NYSE: DCI) is a global leader in technology-led filtration products and solutions, serving a broad range of industries and advanced markets. Our diverse, skilled employees at over 140 locations on six continents partner with customers—from small business owners to the world’s biggest OEM brands—to solve complex filtration challenges. Discover how Donaldson is Advancing Filtration for a Cleaner World at www.Donaldson.com.
What is the purpose of Donaldson's acquisition of Isolere Bio?
The acquisition aims to enhance Donaldson's capabilities in the life sciences sector by integrating Isolere's IsoTag technology for biopharmaceutical purification.
How will Isolere's technology impact Donaldson's product offerings?
Isolere's IsoTag technology is expected to improve product quality and reduce manufacturing timelines for viral vector purification in cell and gene therapies.
When was the acquisition of Isolere Bio announced?
The acquisition was announced on February 21, 2023.
What are the expected benefits of the Isolere acquisition for DCI investors?
Investors can expect potential revenue growth and enhanced product offerings in the life sciences market due to the integration of Isolere's technology.
